Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

NeuroSearch commences phase II clinical trials of potential antidepressant

Feb. 2, 1999

Vanguard Medica and Elan seek regulatory approval of Miguard in the U.S.

Feb. 2, 1999

AMPA receptor antagonists in the pipeline at Schering

Feb. 2, 1999

Neurobiological Technologies awarded SBIR grant for Xerecept development

Feb. 1, 1999

European Commission approves Betaseron for treatment of SPMS

Jan. 29, 1999

Antipsychotic development candidate selected from carbazolone series by Spanish scientists

Jan. 29, 1999

Neotrofin shows positive results in phase II trial for Alzheimer's disease

Jan. 29, 1999

Angiotech to study paclitaxel for yet another new indication

Jan. 28, 1999

OP-1 protects against cerebral infarct in rat model

Jan. 28, 1999

Recently issued U.S. patent covers new D4 receptor ligands developed at Merck Sharp & Dohme

Jan. 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...